Anthony Oliva, Ph.D., was awarded a total of $4 million through the Part the Cloud Challenge on Neuroinflammation.
There is a critical gap between laboratories where experimental drug are developed and pharmacies where approved medications are dispensed. While the vast increase in our understanding of Alzheimer's has led to the identification of promising targets for new therapies, the process of developing and testing potential therapies is long and complex, taking years and substantial resources. There are few funding sources to support the early-phase studies needed to test drug treatments in people. Many promising research ideas stall due to a lack of funding.
The Part the Cloud Global Research Program was created to address this gap. Founded in 2012 by philanthropist Mikey Hoag, the Part the Cloud movement advances research with the highest probability of slowing, stopping or ultimately curing Alzheimer’s disease. Part the Cloud partners with the Alzheimer’s Association to fund research projects that are specifically designed to accelerate the translation of findings from the laboratory into possible therapies — filling the gap in Alzheimer’s drug development by providing essential support for early-phase clinical studies. The Alzheimer's Association has awarded 55 Part the Cloud research grants since 2013.
Part the Cloud Challenges accelerate progress in high-potential areas of dementia science. Through the Part the Cloud Challenge on Neuroinflammation, four researchers were awarded $1 million each to harness an immune response to treat Alzheimer’s disease. Dr. Anthony Oliva was awarded an additional $3 million to take his project to the next level. Through the Part the Cloud to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer’s disease, six researchers received $1 million each to test innovative compounds to be used for interventions in the earliest stages of dementia. Most recently, Part the Cloud partnered with the Association and Bill Gates to advance research aimed at uncovering underlying brain cell changes, improving timely diagnosis and developing new treatments for Alzheimer’s and all other dementia. More than $24 million from this partnership will propel 16 high-risk, high-reward research projects. A second round of grants will be awarded by the end of 2020.
Part the Cloud also serves as a catalyst in helping researchers receive additional funding for their work. After receiving initial funding from Part the Cloud, grant recipients have gone on to obtain more than $434 million in follow-on funding from the federal government, venture capital firms and other sources.